Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16075552 | 0.84 | MAPT (0.41) | MAPTTSHRSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL16072542 | 0.82 | NPC1 (0.35) | SMN1; SMN2ALDH1A1POLBLMNAKMT2A | |
| SCHEMBL20392801 | 0.81 | L3MBTL1 (0.41) | MAPTTSHRSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL16119715 | 0.81 | TSHR (0.42) | MAPTTSHRSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL27748435 | 0.79 | SIGMAR1 (0.34) | POLBHPGDNPSR1 | |
| SCHEMBL28024347 | 0.79 | SMN1; SMN2 (0.45) | MAPTTSHRSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL18475748 | 0.76 | HCAR2 (0.38) | MAPTTSHRSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL8214792 | 0.75 | ALDH1A1 (0.36) | MAPTTSHRSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL12422447 | 0.75 | SMN1; SMN2 (0.44) | MAPTTSHRSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL18775073 | 0.74 | ALDH1A1 (0.36) | MAPTSMN1; SMN2USP2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-10858317-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200048280-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10450269-B1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-9981939-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9957250-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170355713-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | BIOPHARMA CREDIT PLC (GB) | 2017-12-14 | — | — | US | disclosed |
| US-9802900-B2 | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9776960-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9604999-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160083343-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160031904-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-10450269-B1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | MAPT 4249/4885TSHR 3457/4885SMN1; SMN2 1207/4885 |
| US-20160031904-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-10858317-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20170355713-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20160083343-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-20200048280-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | MAPT 4181/4885TSHR 3518/4885SMN1; SMN2 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.